{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:01:14Z","timestamp":1789052474653,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>International guidelines on the treatment of myasthenia gravis (MG) have been published but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian MG experts for the practical management of MG in Belgium. It includes recommendations for treatment of adult patients with generalized myasthenia gravis (gMG) or ocular myasthenia gravis (oMG). Depending on the MG-related antibody a treatment sequence is suggested with therapies that can be added on if the treatment goal is not achieved. Selection of treatments was based on the level of evidence of efficacy, registration and reimbursement status in Belgium, common daily practice and the personal views and experiences of the authors. The paper reflects the situation in February 2024. In addition to the treatment considerations, other relevant aspects in the management of MG are addressed, including comorbidities, drugs aggravating disease symptoms, pregnancy, and vaccination. As many new treatments might potentially come to market, a realistic future perspective on the impact of these treatments on clinical practice is given. In conclusion, these recommendations intend to be a guide for neurologists treating patients with MG in Belgium.<\/jats:p>","DOI":"10.1007\/s13760-024-02552-7","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:29:32Z","timestamp":1713817772000},"page":"1371-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Recommendations for the management of myasthenia gravis in Belgium"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1328-1812","authenticated-orcid":false,"given":"Jan L.","family":"De Bleecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-3570","authenticated-orcid":false,"given":"Gauthier","family":"Remiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2200-9255","authenticated-orcid":false,"given":"Alicia","family":"Alonso-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-123X","authenticated-orcid":false,"given":"Vinciane","family":"Van Parys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-8725","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Bissay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-579X","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Delstanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-443X","authenticated-orcid":false,"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"2552_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223322","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wang B, Hao Y, Zhu R (2023) Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases. Frond Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1223322","journal-title":"Frond Immunol"},{"key":"2552_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"A-M Bubuioc","year":"2021","unstructured":"Bubuioc A-M, Kudebayeva A, Turuspekova S et al (2021) The epidemiology of myasthenia gravis. J Med Life 14:7\u201316. https:\/\/doi.org\/10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"2552_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J et al (2023) Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord 33:324\u2013333. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","journal-title":"Neuromuscul Disord"},{"key":"2552_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","volume":"11","author":"K O\u2019Connell","year":"2020","unstructured":"O\u2019Connell K, Ramdas S, Palace J (2020) Management of Juvenile myasthenia gravis. Front Neurol 11:743. https:\/\/doi.org\/10.3389\/fneur.2020.00743","journal-title":"Front Neurol"},{"key":"2552_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13760-023-02187-0","volume":"123","author":"R Mercelis","year":"2023","unstructured":"Mercelis R, Alonso-Jim\u00e9nez A, Van Schil P (2023) Current management of myasthenia gravis in Belgium: a single-center experience. Acta Neurol Belg 123:375\u2013384. https:\/\/doi.org\/10.1007\/s13760-023-02187-0","journal-title":"Acta Neurol Belg"},{"key":"2552_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos SJ, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30","journal-title":"Nat Rev Dis Primers"},{"key":"2552_CR7","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S et al (2023) People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies. Adv Ther 40:4377\u20134394. https:\/\/doi.org\/10.1007\/s12325-023-02604-z","journal-title":"Adv Ther"},{"key":"2552_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M et al (2021) The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther 10:1103\u20131125. https:\/\/doi.org\/10.1007\/s40120-021-00285-w","journal-title":"Neurol Ther"},{"key":"2552_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01616412.2023.2257449","volume":"46","author":"P Ye\u015fil Demirci","year":"2023","unstructured":"Ye\u015fil Demirci P, Eskimez Z, Bozdo\u011fan Ye\u015filot S (2023) The influence of symptom severity and fatigue on sleep quality in patients with myasthenia gravis. Neurol Res 46:1\u20137. https:\/\/doi.org\/10.1080\/01616412.2023.2257449","journal-title":"Neurol Res"},{"key":"2552_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202119","author":"J Pesa","year":"2023","unstructured":"Pesa J, Chaudhry Z, de Courcy J et al (2023) The impact of generalized myasthenia gravis severity on work and daily activities: a real world study (P7-8.006). Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000202119","journal-title":"Neurology"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1:16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918","journal-title":"Neurohospitalist"},{"key":"2552_CR12","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"DL Longo","year":"2016","unstructured":"Longo DL, Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"2552_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117549","volume":"427","author":"SM Laakso","year":"2021","unstructured":"Laakso SM, Myllynen C, Strbian D, Atula S (2021) Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy. J Neurol Sci 427:117549. https:\/\/doi.org\/10.1016\/j.jns.2021.117549","journal-title":"J Neurol Sci"},{"key":"2552_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1602489","journal-title":"N Engl J Med"},{"key":"2552_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, GilI W, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis. Neurology 87:419. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"issue":"3","key":"2552_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis 2020 Update. Neurology 96(3):114\u2013122.\u00a0https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"2552_CR17","unstructured":"Autoimmuun Myasthenia Gravis: Consensus richtlijn. Spierziektencentrum Nederland. 2022"},{"key":"2552_CR18","unstructured":"Wiendl H, Meisel A. Diagnostik und Therapie myasthener Syndrome. 2022 Nov. Report No. 030\/087: Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"key":"2552_CR19","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"2552_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/nyas.13503","volume":"1412","author":"JF Sussman","year":"2018","unstructured":"Sussman JF, Farrugia ME, Maddison P et al (2018) The Association of British Neurologists\u2019 myasthenia gravis guidelines. Ann N Y Acad Sci 1412:166\u2013169","journal-title":"Ann N Y Acad Sci"},{"key":"2552_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P et al (2015) Myasthenia gravis: Association of British Neurologists\u2019 management guidelines. Pract Neurol 15:199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126","journal-title":"Pract Neurol"},{"key":"2552_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R et al (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65:630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"key":"2552_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"2552_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.000000000020024","volume":"14","author":"M Nguyen","year":"2024","unstructured":"Nguyen M, Clough M, Cruse B et al (2024) Exploring factors that prolong the diagnosis of myasthenia gravis. Neurol Clin Pract 14:e200244. https:\/\/doi.org\/10.1212\/CPJ.000000000020024","journal-title":"Neurol Clin Pract"},{"key":"2552_CR25","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D et al (2021) Patient-reported symptom severity in a nationwide myasthenia gravis cohort. Neurology 97:e1382\u2013e1391. https:\/\/doi.org\/10.1212\/WNL.0000000000012604","journal-title":"Neurology"},{"key":"2552_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","volume":"24","author":"Y Hong","year":"2017","unstructured":"Hong Y, Zisimopoulou P, Trakas N et al (2017) Multiple antibody detection in \u2018seronegative\u2019 myasthenia gravis patients. Eur J Neurol 24:844\u2013850. https:\/\/doi.org\/10.1111\/ene.13300","journal-title":"Eur J Neurol"},{"key":"2552_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of myasthenia gravis. Neurol Clin 36:311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"key":"2552_CR28","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94:e1171\u2013e1180. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"key":"2552_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11940-014-0283-8","volume":"16","author":"K El-Salem","year":"2014","unstructured":"El-Salem K, Yassin A, Al-Hayk K et al (2014) Treatment of MuSK-associated myasthenia gravis. Curr Treat Options Neurol 16:283","journal-title":"Curr Treat Options Neurol"},{"key":"2552_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Xinli Du (2023) New and emerging treatments for myasthenia gravis. BMJ Med 2:e000241. https:\/\/doi.org\/10.1136\/bmjmed-2022-000241","journal-title":"BMJ Med"},{"key":"2552_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S (2008) Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 4:317\u2013327","journal-title":"Nat Clin Pract Neurol"},{"key":"2552_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","volume":"36","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R (2023) Current drug treatment of myasthenia gravis. Curr Opin Neurol 36:410\u2013415. https:\/\/doi.org\/10.1097\/WCO.0000000000001196","journal-title":"Curr Opin Neurol"},{"key":"2552_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","volume":"15","author":"C Bernard","year":"2016","unstructured":"Bernard C, Frih H, Pasquet F et al (2016) Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 15:82\u201392. https:\/\/doi.org\/10.1016\/j.autrev.2015.09.005","journal-title":"Autoimmun Rev"},{"key":"2552_CR34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37584","volume":"15","author":"I Khawaja","year":"2023","unstructured":"Khawaja I (2023) Effect of thymectomy on outcomes of myasthenia gravis patients: a case-control study at a Tertiary Care Hospital. Cureus 15:e37584. https:\/\/doi.org\/10.7759\/cureus.37584","journal-title":"Cureus"},{"key":"2552_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JFJ Howard","year":"2021","unstructured":"Howard JFJ, Bril V, Vu T et al (2021) Safety, efficacy and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"2552_CR36","doi-asserted-by":"publisher","first-page":"596621","DOI":"10.3389\/fneur.2020.596621","volume":"11","author":"H Frykman","year":"2020","unstructured":"Frykman H, Kumar P, Oger J (2020) Immunopathology of autoimmune myasthenia gravies: implications for improved testing algorithms and treatment strategies. Front Neurol 11:596621. https:\/\/doi.org\/10.3389\/fneur.2020.596621","journal-title":"Front Neurol"},{"key":"2552_CR37","doi-asserted-by":"publisher","first-page":"175628642311638","DOI":"10.1177\/17562864231163819","volume":"16","author":"T Narita","year":"2023","unstructured":"Narita T, Nakane S, Nagaishi A et al (2023) Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Ther Adv Neurol Disord 16:17562864231163820. https:\/\/doi.org\/10.1177\/17562864231163819","journal-title":"Ther Adv Neurol Disord"},{"key":"2552_CR38","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s13311-022-01335-3","volume":"20","author":"A Uzawa","year":"2023","unstructured":"Uzawa A, Suzuki S, Kuwabara S et al (2023) Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis. Neurotherapeutics 20:518\u2013523. https:\/\/doi.org\/10.1007\/s13311-022-01335-3","journal-title":"Neurotherapeutics"},{"key":"2552_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S389629","volume":"15","author":"R Behbehani","year":"2023","unstructured":"Behbehani R (2023) Ocular myasthenia gravis: a current overview. Eye Brain 15:1\u201313. https:\/\/doi.org\/10.2147\/EB.S389629","journal-title":"Eye Brain"},{"key":"2552_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.605902","author":"A Evoli","year":"2020","unstructured":"Evoli A, Iorio R (2020) Controversies in ocular myasthenia gravis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.605902","journal-title":"Front Neurol"},{"key":"2552_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","volume":"37","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A (2023) Efgartigimod alfa in generalised myasthenia gravis: a profile of its Use. CNS Drugs 37:467\u2013473. https:\/\/doi.org\/10.1007\/s40263-023-01000-z","journal-title":"CNS Drugs"},{"key":"2552_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12883-023-03306-3","volume":"23","author":"C-Y Chien","year":"2023","unstructured":"Chien C-Y, Chang C-W, Liao M-F et al (2023) Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study. BMC Neurol 23:255. https:\/\/doi.org\/10.1186\/s12883-023-03306-3","journal-title":"BMC Neurol"},{"key":"2552_CR43","first-page":"CD0002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:CD0002277","journal-title":"Cochrane Database Syst Rev"},{"key":"2552_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17\u201323","journal-title":"Eur J Neurol"},{"key":"2552_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.790941","author":"J Shi","year":"2021","unstructured":"Shi J, Huan X, Zhou L et al (2021) Comorbid autoimmune diseases in patients with myasthenia gravis: a retrospective cross-sectional study of a Chinese Cohort. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.790941","journal-title":"Front Neurol"},{"key":"2552_CR46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"Y-T Huang","year":"2020","unstructured":"Huang Y-T, Chen Y-P, Lin W-C et al (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634. https:\/\/doi.org\/10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"2552_CR47","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K (2021) Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med 10:1537. https:\/\/doi.org\/10.3390\/jcm10071537","journal-title":"J Clin Med"},{"key":"2552_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00554","author":"NE Gilhus","year":"2020","unstructured":"Gilhus NE (2020) Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.00554","journal-title":"Front Neurol"},{"key":"2552_CR49","first-page":"1346","volume":"58","author":"SA Chaudry","year":"2012","unstructured":"Chaudry SA, Vignarajah B, Koren G (2012) Myasthenia gravis during pregnancy. Can Fam Physician 58:1346","journal-title":"Can Fam Physician"},{"key":"2552_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neurol.2020.09.015","volume":"177","author":"P Roche","year":"2021","unstructured":"Roche P, Bouhour F (2021) Myasthenia gravis and pregnancy. Rev Neurol (Paris) 177:215\u2013219. https:\/\/doi.org\/10.1016\/j.neurol.2020.09.015","journal-title":"Rev Neurol (Paris)"},{"key":"2552_CR51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","volume":"85","author":"F Norwood","year":"2013","unstructured":"Norwood F, Dhanjal M, Hill M et al (2013) Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 85:538\u2013543","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2552_CR52","volume":"15","author":"L Kumar","year":"2023","unstructured":"Kumar L, Kacchadia M, Kaur J (2023) Choices and challenges with treatment of myasthenia gravis in pregnancy: a systematic review. Cureus 15:e42772","journal-title":"Cureus"},{"key":"2552_CR53","doi-asserted-by":"publisher","first-page":"102525","DOI":"10.1016\/j.autrev.2020.102525","volume":"19","author":"C Belizna","year":"2020","unstructured":"Belizna C, Meroni PL, Shoenfeld Y et al (2020) In utero exposure to Azathioprine in autoimmune disease. Where do we stand? Autoimmun Rev 19:102525. https:\/\/doi.org\/10.1016\/j.autrev.2020.102525","journal-title":"Autoimmun Rev"},{"key":"2552_CR54","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4103\/ijp.IJP_452_17","volume":"50","author":"R Bansal","year":"2018","unstructured":"Bansal R, Goyal MK, Modi M (2018) Management of myasthenia gravis during pregnancy. Indian J Pharmacol 50:302\u2013308. https:\/\/doi.org\/10.4103\/ijp.IJP_452_17","journal-title":"Indian J Pharmacol"},{"key":"2552_CR55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tose M-P, Marantz JL et al (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"2552_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000511957","volume":"13","author":"T Vu","year":"2021","unstructured":"Vu T, Harvey B, Suresh N et al (2021) Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol 13:65\u201372. https:\/\/doi.org\/10.1159\/000511957","journal-title":"Case Rep Neurol"},{"key":"2552_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1103020","author":"S Peng","year":"2022","unstructured":"Peng S, Tian Y, Meng L et al (2022) The safety of COVID-19 vaccines in patients with myasthenia gravis: a scoping review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1103020","journal-title":"Front Immunol"},{"key":"2552_CR58","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","volume":"269","author":"G Sansone","year":"2022","unstructured":"Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269:3965\u20133981. https:\/\/doi.org\/10.1007\/s00415-022-11140-9","journal-title":"J Neurol"},{"key":"2552_CR59","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:175628641983224","journal-title":"Ther Adv Neurol Disord"},{"key":"2552_CR60","doi-asserted-by":"publisher","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","volume":"14","author":"A Vesperinas-Castro","year":"2023","unstructured":"Vesperinas-Castro A, Cort\u00e9s-Vicente E (2023) Rituximab treatment in myasthenia gravis. Front Neurol 14:1275533. https:\/\/doi.org\/10.3389\/fneur.2023.1275533","journal-title":"Front Neurol"},{"key":"2552_CR61","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evidence 1:EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evidence"},{"key":"2552_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JFJ Howard","year":"2023","unstructured":"Howard JFJ, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"2552_CR63","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JFJ Howard","year":"2017","unstructured":"Howard JFJ, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravies (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"2552_CR64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"2552_CR65","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"2552_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S (2023) Novel Immunotherapies for Myasthenia Gravis. ITT 12:25\u201345","journal-title":"ITT"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02552-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02552-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02552-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:45:10Z","timestamp":1721789110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02552-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02552-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JLDB received speaker and\/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, argenX, Biogen, CSL Behring, Janssen Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB. GR received speaker and\/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, Amlynx, argenX, CSL Behring, Effik, Pfizer, Roche, Sanofi-Genzyme, and UCB. AA received advisory board honoraria from Alexion and UCB. VVP received advisory board honoraria from Alexion, and Alnylam. VB received advisory board honoraria from Alexion and UCB. SD received advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, Amlynx, argenX, Biogen, CSL Behring, Janssen Pharmaceuticals, and UCB. KGC received speaker and\/or advisory board honoraria from Alexion, Alnylam, Amicus Therapeutics, argenX, Biogen, Ipsen, Janssen Pharmaceuticals, Lupin, Pfizer, Roche, Sanofi-Genzyme, and UCB. KGC is Chairholder of the Emil von Behring Chair for Neuromuscular and Neurodegenerative Disorders by CSL Behring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participates or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}